Wedbush analyst David Nierengarten lowered his price target for Karyopharm to $6 from $14 following the outcome of the FDA Advisory Committee Meeting regarding the potential approval of selinexor in penta-refractory multiple myeloma by the PDUFA date of April 6, 2019. The analyst notes that the panel voted 8 yes to 5 no to the question of "Should the approval of selinexor be delayed until results of the randomized phase 3 trial, BOSTON, are available?," as key concerns around safety, dose reductions and study design previously introduced in the published briefing docs prevailed, although the vote also indicated a receptiveness, particularly among treating physicians, for a novel drug like selinexor that could help serve this highly refractory patient population with limited treatment options. Nierengarten reiterates an Outperform rating on the shares.